{"id":{"repo_id":"cornell","oai_identifier":"oai:ecommons.cornell.edu:1813/51622"},"canonical_url":"https://search.ndltd.org/etd/cornell/oai:ecommons.cornell.edu:1813/51622","repository":{"repo_id":"cornell","name":"Cornell University","base_url":"https://ecommons.cornell.edu/server/oai/request"},"display":{"title":"MECHANISTIC UNDERSTANDING OF RIBONUCLEOTIDE REDUCTASE INHIBITION BY HALOGENATED NUCLEOTIDE ANTICANCER AGENTS","abstract":"ABSTRACT Ribonucleotide reductase (RNR) is an enzyme that catalyzes the conversion of ribonucleotides to C2ʹ-deoxyribonucleotides, the building blocks for both DNA synthesis and repair in all living organisms, via controlled radical chemistry. Since RNR expression is elevated in many cancers, this enzyme is a major target of anticancer drugs. Until recently, the only clinically proven RNR-inhibition pathway was a suicide inactivation in which synthetic substrate analogues, for instance, gemcitabine diphosphate (F2CDP), irreversibly inactivate the RNR-α2β2 heterodimeric complex. Recently, Clofarabine (ClF) nucleotides have been shown to reversibly inhibit the enzyme by targeting the large subunit of RNR (RNR-α) and inducing RNR- α-persistent hexamerization. To date, ClF nucleotides are the only known examples of this mechanism. In order to establish whether this reversible inhibition is a common mode of inhibition among nucleotide-derivative drugs, the active forms of two other drugs, Cladribine (ClA) and Fludarabine (FlU), were chemoenzymatically synthesized and their mechanism(s) of inhibition of RNR were evaluated. Enzyme inhibition and fluorescence anisotropy assays show that di- and triphosphates of these two nucleosides reversibly inhibit RNR with diverse Ki values, fairly dispersed in a range of 0.5–10 μM, and bind to the catalytic site (C-site) and the allosteric activity site (A- site) of RNR-α, respectively. Our EM studies, gel filtration, FRET, and protease digestion assays suggest that RNR-inhibition is coupled with the formation of conformationally distinct hexamers. Studies in Flp-In HEK293 T-REx cells capable of selectively inducing either wild-type or oligomerization-defective mutant RNR-α overexpression define the central role of RNR-α oligomerization in drug activity, and highlight a potential resistant mechanism to these drugs. The results of these studies set the stage for new interventions targeting RNR oligomeric regulation.","abstract_html":"ABSTRACT Ribonucleotide reductase (RNR) is an enzyme that catalyzes the conversion of ribonucleotides to C2ʹ-deoxyribonucleotides, the building blocks for both DNA synthesis and repair in all living organisms, via controlled radical chemistry. Since RNR expression is elevated in many cancers, this enzyme is a major target of anticancer drugs. Until recently, the only clinically proven RNR-inhibition pathway was a suicide inactivation in which synthetic substrate analogues, for instance, gemcitabine diphosphate (F2CDP), irreversibly inactivate the RNR-α2β2 heterodimeric complex. Recently, Clofarabine (ClF) nucleotides have been shown to reversibly inhibit the enzyme by targeting the large subunit of RNR (RNR-α) and inducing RNR- α-persistent hexamerization. To date, ClF nucleotides are the only known examples of this mechanism. In order to establish whether this reversible inhibition is a common mode of inhibition among nucleotide-derivative drugs, the active forms of two other drugs, Cladribine (ClA) and Fludarabine (FlU), were chemoenzymatically synthesized and their mechanism(s) of inhibition of RNR were evaluated. Enzyme inhibition and fluorescence anisotropy assays show that di- and triphosphates of these two nucleosides reversibly inhibit RNR with diverse Ki values, fairly dispersed in a range of 0.5–10 μM, and bind to the catalytic site (C-site) and the allosteric activity site (A- site) of RNR-α, respectively. Our EM studies, gel filtration, FRET, and protease digestion assays suggest that RNR-inhibition is coupled with the formation of conformationally distinct hexamers. Studies in Flp-In HEK293 T-REx cells capable of selectively inducing either wild-type or oligomerization-defective mutant RNR-α overexpression define the central role of RNR-α oligomerization in drug activity, and highlight a potential resistant mechanism to these drugs. The results of these studies set the stage for new interventions targeting RNR oligomeric regulation.","abstract_has_math":false,"creators":["Wisitpitthaya, Somsinee"],"institution":"Cornell University","degree_name":"Ph. D., Chemistry and Chemical Biology","degree_level":"Doctor of Philosophy","degree_discipline":"Chemistry and Chemical Biology","degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":["Aye, Yimon"],"committee_members":["Lin, Hening","Coates, Geoffrey"],"year":2017,"date_issued":"2017-05-30","date_published":"2017-05-30","updated_at":"2026-11-19T03:19:41Z","subjects":["Chemistry","Biochemistry","Cladribine","Fludarabine","Hexamerization","Oligomeric regulation","Ribonucleotide Reductase","RNR"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.doi","label":"DOI","values":["https://doi.org/10.7298/X4XW4GX1"],"render_values":[{"text":"https://doi.org/10.7298/X4XW4GX1","href":"https://doi.org/10.7298/X4XW4GX1","code":true}]},{"key":"dc:identifier.bibid","label":"Dc Identifier Bibid","values":["9948845"],"render_values":[{"text":"9948845","href":null,"code":true}]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["ProQuest Submission ID: 10215","ProQuest Publication ID: 10260013"],"render_values":[{"text":"ProQuest Submission ID: 10215","href":null,"code":true},{"text":"ProQuest Publication ID: 10260013","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/1813/51622","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/1813/51622","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://ecommons.cornell.edu/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aecommons.cornell.edu%3A1813%2F51622","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.chair","label":"Chair","values":["Aye, Yimon"]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Lin, Hening","Coates, Geoffrey"]},{"key":"dc:creator","label":"Author","values":["Wisitpitthaya, Somsinee"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2017-07-07T12:48:42Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2019-06-08T06:01:45Z"]},{"key":"dc:date.issued","label":"Date","values":["2017-05-30"]},{"key":"dc:type","label":"Dc Type","values":["dissertation or thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry and Chemical Biology"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Doctor of Philosophy"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph. D., Chemistry and Chemical Biology"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Cornell University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Chemistry","Biochemistry","Cladribine","Fludarabine","Hexamerization","Oligomeric regulation","Ribonucleotide Reductase","RNR"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.bibid","label":"Dc Identifier Bibid","values":["9948845"]},{"key":"dc:identifier.doi","label":"DOI","values":["https://doi.org/10.7298/X4XW4GX1"]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["ProQuest Submission ID: 10215","ProQuest Publication ID: 10260013"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/1813/51622"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"cerif:openaire","label":"Cerif Openaire","values":["<Publication xmlns=\"https://www.openaire.eu/cerif-profile/1.1/\" id=\"b1a90645-fe0f-49ee-a694-0195060ccecd\"> <Type xmlns=\"https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types\">http://purl.org/coar/resource_type/c_1843</Type> <Language>en_US</Language> <Title>MECHANISTIC UNDERSTANDING OF RIBONUCLEOTIDE REDUCTASE INHIBITION BY HALOGENATED NUCLEOTIDE ANTICANCER AGENTS</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2017-05-30</PublicationDate> <DOI>https://doi.org/10.7298/X4XW4GX1</DOI> <Authors> <Author> <DisplayName>Wisitpitthaya, Somsinee</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <OrgUnit /> </Publisher> </Publishers> <Keyword>Chemistry</Keyword> <Keyword>Biochemistry</Keyword> <Keyword>Cladribine</Keyword> <Keyword>Fludarabine</Keyword> <Keyword>Hexamerization</Keyword> <Keyword>Oligomeric regulation</Keyword> <Keyword>Ribonucleotide Reductase</Keyword> <Keyword>RNR</Keyword> <Abstract>ABSTRACT Ribonucleotide reductase (RNR) is an enzyme that catalyzes the conversion of ribonucleotides to C2ʹ-deoxyribonucleotides, the building blocks for both DNA synthesis and repair in all living organisms, via controlled radical chemistry. Since RNR expression is elevated in many cancers, this enzyme is a major target of anticancer drugs. Until recently, the only clinically proven RNR-inhibition pathway was a suicide inactivation in which synthetic substrate analogues, for instance, gemcitabine diphosphate (F2CDP), irreversibly inactivate the RNR-α2β2 heterodimeric complex. Recently, Clofarabine (ClF) nucleotides have been shown to reversibly inhibit the enzyme by targeting the large subunit of RNR (RNR-α) and inducing RNR- α-persistent hexamerization. To date, ClF nucleotides are the only known examples of this mechanism. In order to establish whether this reversible inhibition is a common mode of inhibition among nucleotide-derivative drugs, the active forms of two other drugs, Cladribine (ClA) and Fludarabine (FlU), were chemoenzymatically synthesized and their mechanism(s) of inhibition of RNR were evaluated. Enzyme inhibition and fluorescence anisotropy assays show that di- and triphosphates of these two nucleosides reversibly inhibit RNR with diverse Ki values, fairly dispersed in a range of 0.5–10 μM, and bind to the catalytic site (C-site) and the allosteric activity site (A- site) of RNR-α, respectively. Our EM studies, gel filtration, FRET, and protease digestion assays suggest that RNR-inhibition is coupled with the formation of conformationally distinct hexamers. Studies in Flp-In HEK293 T-REx cells capable of selectively inducing either wild-type or oligomerization-defective mutant RNR-α overexpression define the central role of RNR-α oligomerization in drug activity, and highlight a potential resistant mechanism to these drugs. The results of these studies set the stage for new interventions targeting RNR oligomeric regulation.</Abstract> <Access xmlns=\"http://purl.org/coar/access_right\" > </Access> </Publication>"]},{"key":"cris:virtual.author","label":"Cris Virtual Author","values":["Wisitpitthaya, Somsinee"]},{"key":"cris:virtualsource.collection","label":"Cris Virtualsource Collection","values":["5893a6ea-7af3-41d7-abc6-04bcd26ab5df"]},{"key":"dc:description.abstract","label":"Abstract","values":["ABSTRACT Ribonucleotide reductase (RNR) is an enzyme that catalyzes the conversion of ribonucleotides to C2ʹ-deoxyribonucleotides, the building blocks for both DNA synthesis and repair in all living organisms, via controlled radical chemistry. Since RNR expression is elevated in many cancers, this enzyme is a major target of anticancer drugs. Until recently, the only clinically proven RNR-inhibition pathway was a suicide inactivation in which synthetic substrate analogues, for instance, gemcitabine diphosphate (F2CDP), irreversibly inactivate the RNR-α2β2 heterodimeric complex. Recently, Clofarabine (ClF) nucleotides have been shown to reversibly inhibit the enzyme by targeting the large subunit of RNR (RNR-α) and inducing RNR- α-persistent hexamerization. To date, ClF nucleotides are the only known examples of this mechanism. In order to establish whether this reversible inhibition is a common mode of inhibition among nucleotide-derivative drugs, the active forms of two other drugs, Cladribine (ClA) and Fludarabine (FlU), were chemoenzymatically synthesized and their mechanism(s) of inhibition of RNR were evaluated. Enzyme inhibition and fluorescence anisotropy assays show that di- and triphosphates of these two nucleosides reversibly inhibit RNR with diverse Ki values, fairly dispersed in a range of 0.5–10 μM, and bind to the catalytic site (C-site) and the allosteric activity site (A- site) of RNR-α, respectively. Our EM studies, gel filtration, FRET, and protease digestion assays suggest that RNR-inhibition is coupled with the formation of conformationally distinct hexamers. Studies in Flp-In HEK293 T-REx cells capable of selectively inducing either wild-type or oligomerization-defective mutant RNR-α overexpression define the central role of RNR-α oligomerization in drug activity, and highlight a potential resistant mechanism to these drugs. The results of these studies set the stage for new interventions targeting RNR oligomeric regulation."]},{"key":"dc:description.collection","label":"Dc Description Collection","values":["Cornell Theses and Dissertations"]},{"key":"dc:format.mimetype","label":"Dc Format Mimetype","values":["application/pdf"]},{"key":"dcterms:license","label":"Dcterms License","values":["https://hdl.handle.net/1813/59810"]},{"key":"dc:title","label":"Title","values":["MECHANISTIC UNDERSTANDING OF RIBONUCLEOTIDE REDUCTASE INHIBITION BY HALOGENATED NUCLEOTIDE ANTICANCER AGENTS"]},{"key":"dspace:entity.type","label":"Dspace Entity Type","values":["Publication"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"cerif:openaire":["<Publication xmlns=\"https://www.openaire.eu/cerif-profile/1.1/\" id=\"b1a90645-fe0f-49ee-a694-0195060ccecd\"> <Type xmlns=\"https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types\">http://purl.org/coar/resource_type/c_1843</Type> <Language>en_US</Language> <Title>MECHANISTIC UNDERSTANDING OF RIBONUCLEOTIDE REDUCTASE INHIBITION BY HALOGENATED NUCLEOTIDE ANTICANCER AGENTS</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2017-05-30</PublicationDate> <DOI>https://doi.org/10.7298/X4XW4GX1</DOI> <Authors> <Author> <DisplayName>Wisitpitthaya, Somsinee</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <OrgUnit /> </Publisher> </Publishers> <Keyword>Chemistry</Keyword> <Keyword>Biochemistry</Keyword> <Keyword>Cladribine</Keyword> <Keyword>Fludarabine</Keyword> <Keyword>Hexamerization</Keyword> <Keyword>Oligomeric regulation</Keyword> <Keyword>Ribonucleotide Reductase</Keyword> <Keyword>RNR</Keyword> <Abstract>ABSTRACT Ribonucleotide reductase (RNR) is an enzyme that catalyzes the conversion of ribonucleotides to C2ʹ-deoxyribonucleotides, the building blocks for both DNA synthesis and repair in all living organisms, via controlled radical chemistry. Since RNR expression is elevated in many cancers, this enzyme is a major target of anticancer drugs. Until recently, the only clinically proven RNR-inhibition pathway was a suicide inactivation in which synthetic substrate analogues, for instance, gemcitabine diphosphate (F2CDP), irreversibly inactivate the RNR-α2β2 heterodimeric complex. Recently, Clofarabine (ClF) nucleotides have been shown to reversibly inhibit the enzyme by targeting the large subunit of RNR (RNR-α) and inducing RNR- α-persistent hexamerization. To date, ClF nucleotides are the only known examples of this mechanism. In order to establish whether this reversible inhibition is a common mode of inhibition among nucleotide-derivative drugs, the active forms of two other drugs, Cladribine (ClA) and Fludarabine (FlU), were chemoenzymatically synthesized and their mechanism(s) of inhibition of RNR were evaluated. Enzyme inhibition and fluorescence anisotropy assays show that di- and triphosphates of these two nucleosides reversibly inhibit RNR with diverse Ki values, fairly dispersed in a range of 0.5–10 μM, and bind to the catalytic site (C-site) and the allosteric activity site (A- site) of RNR-α, respectively. Our EM studies, gel filtration, FRET, and protease digestion assays suggest that RNR-inhibition is coupled with the formation of conformationally distinct hexamers. Studies in Flp-In HEK293 T-REx cells capable of selectively inducing either wild-type or oligomerization-defective mutant RNR-α overexpression define the central role of RNR-α oligomerization in drug activity, and highlight a potential resistant mechanism to these drugs. The results of these studies set the stage for new interventions targeting RNR oligomeric regulation.</Abstract> <Access xmlns=\"http://purl.org/coar/access_right\" > </Access> </Publication>"],"cris:virtual.author":["Wisitpitthaya, Somsinee"],"cris:virtualsource.collection":["5893a6ea-7af3-41d7-abc6-04bcd26ab5df"],"dc:contributor.chair":["Aye, Yimon"],"dc:contributor.committeemember":["Lin, Hening","Coates, Geoffrey"],"dc:creator":["Wisitpitthaya, Somsinee"],"dc:date.accessioned":["2017-07-07T12:48:42Z"],"dc:date.available":["2019-06-08T06:01:45Z"],"dc:date.issued":["2017-05-30"],"dc:description.abstract":["ABSTRACT Ribonucleotide reductase (RNR) is an enzyme that catalyzes the conversion of ribonucleotides to C2ʹ-deoxyribonucleotides, the building blocks for both DNA synthesis and repair in all living organisms, via controlled radical chemistry. Since RNR expression is elevated in many cancers, this enzyme is a major target of anticancer drugs. Until recently, the only clinically proven RNR-inhibition pathway was a suicide inactivation in which synthetic substrate analogues, for instance, gemcitabine diphosphate (F2CDP), irreversibly inactivate the RNR-α2β2 heterodimeric complex. Recently, Clofarabine (ClF) nucleotides have been shown to reversibly inhibit the enzyme by targeting the large subunit of RNR (RNR-α) and inducing RNR- α-persistent hexamerization. To date, ClF nucleotides are the only known examples of this mechanism. In order to establish whether this reversible inhibition is a common mode of inhibition among nucleotide-derivative drugs, the active forms of two other drugs, Cladribine (ClA) and Fludarabine (FlU), were chemoenzymatically synthesized and their mechanism(s) of inhibition of RNR were evaluated. Enzyme inhibition and fluorescence anisotropy assays show that di- and triphosphates of these two nucleosides reversibly inhibit RNR with diverse Ki values, fairly dispersed in a range of 0.5–10 μM, and bind to the catalytic site (C-site) and the allosteric activity site (A- site) of RNR-α, respectively. Our EM studies, gel filtration, FRET, and protease digestion assays suggest that RNR-inhibition is coupled with the formation of conformationally distinct hexamers. Studies in Flp-In HEK293 T-REx cells capable of selectively inducing either wild-type or oligomerization-defective mutant RNR-α overexpression define the central role of RNR-α oligomerization in drug activity, and highlight a potential resistant mechanism to these drugs. The results of these studies set the stage for new interventions targeting RNR oligomeric regulation."],"dc:description.collection":["Cornell Theses and Dissertations"],"dc:format.mimetype":["application/pdf"],"dc:identifier.bibid":["9948845"],"dc:identifier.doi":["https://doi.org/10.7298/X4XW4GX1"],"dc:identifier.other":["ProQuest Submission ID: 10215","ProQuest Publication ID: 10260013"],"dc:identifier.uri":["https://hdl.handle.net/1813/51622"],"dc:language.iso":["en_US"],"dc:subject":["Chemistry","Biochemistry","Cladribine","Fludarabine","Hexamerization","Oligomeric regulation","Ribonucleotide Reductase","RNR"],"dcterms:license":["https://hdl.handle.net/1813/59810"],"dc:title":["MECHANISTIC UNDERSTANDING OF RIBONUCLEOTIDE REDUCTASE INHIBITION BY HALOGENATED NUCLEOTIDE ANTICANCER AGENTS"],"dc:type":["dissertation or thesis"],"dspace:entity.type":["Publication"],"others:access_status":["open.access"],"thesis:degree_discipline":["Chemistry and Chemical Biology"],"thesis:degree_level":["Doctor of Philosophy"],"thesis:degree_name":["Ph. D., Chemistry and Chemical Biology"],"thesis:institution_name":["Cornell University"]},"updated_at":"2026-11-19T03:19:41Z"}